

- Unique Formula: chlorcyclizine HCl 25 mg (antihistamine, NOT chlorpheniramine), pseudoephedrine HCl 60 mg (decongestant).
- The antihistamine chlorcyclizine HCl has a prolonged action and a lower incidence of drowsiness (Goodman & Gilman, 2011).
- Anticholinergic control of rhinorrhea [and postnasal drip] among first-generation antihistamines (Wallace & Dykewicz, 2008).
- · Lower dosage of pseudoephedrine (60 mg per tablet).
- Dosage can be titrated up to three times per day (up to one tablet every 6 hours, maximum three tablets per day) according to individual patient needs; also scored tablet.

Each Stahist™ AD tablet contains:

Chlorcyclizine HCI	25mg
Pseudoephedrine HCI	60ma

Directions

Do not exceed recommended dosage.

•	
Adults and children 12 years of age and over:	1 tablet by mouth every 6 hours, not to exceed
	3 tablets in 24 hours, or as directed by a doctor
Children 6 to under 12 years of age:	½ tablet by mouth every 6 hours, not to exceed 1½ tablets in 24 hours, or as directed by a doctor
Children under 6 years of age	Consult a doctor

Pick Numbers:

McKesson #2229375, ABC #10102832, Cardinal #4551826, CVS #126259, Miami-Luken #161-331, ANDA #503101, Smith Drug #573378, H.D. Smith #255-7288



Stahist™ ADAntihistamine • Nasal Decongestant

Drug Facts

Active Ingredients

(in each immediate-release tablet)

Purpose
Chlorovelizing HCL25 mg

Chlorcyclizine HCI 25 mgAntihistamine
Pseudoephedrine HCI 60 mgNasal Decongestant

NDC 58407-625-30

Uses temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies:

•runny nose •sneezing •itching of the nose or throat • itchy, watery eyes •nasal congestion •reduces swelling of nasal passages

Warnings

Do not exceed recommended dosage.

Do not use this product

 If you are taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for two weeks after stopping the MAOI drug. If you do not know if your prescription drug contains MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

 a breathing problem such as emphysema or chronic bronchitis ● glaucoma ● heart disease ● high blood pressure ● thyroid disease ● diabetes melitus ● difficulty in urination due to enlargement of the prostate gland

Ask a doctor before use if you are taking sedatives or tranquilizers When using this product

- · excitability may occur, especially in children
- may cause drowsiness
- alcohol, sedatives and tranquilizers may increase drowsiness effect
- avoid alcoholic beverages
- use caution when driving a motor vehicle or operating machinery

Stop use and ask a doctor if

- · nervousness, dizziness or sleeplessness occur
- symptoms do not improve within 7 days or are accompanied by fever
- new symptoms occur

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children.

In case of accidental overdose, seek professional help or contact a Poison Control Center immediately.

Directions

Do not exceed recommended dosage.

Adults and children 12 years of age and over:	1 tablet by mouth every 6 hours, not to exceed
	3 tablets in 24 hours, or as directed by a doctor
Children 6 to under 12 years of age:	½ tablet by mouth every 6 hours, not to exceed 1½ tablets in 24 hours, or as directed by a doctor
Children under 6 years of age	Consult a doctor

Inactive ingredients

Magnesium Stearate, Microcrystalline Cellulose, Sodium, Starch Glycolate

Questions or Comments?

Call 1-888-206-5525

RETAIN CARTON FOR COMPLETE PRODUCT INFORMATION

Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing. Supplied in a tight, light-resistant container with a child-resistant cap Store at 59°- 86°F (15°- 30°C) [see USP Controlled Room Temperature]

Manufactured for:

MAGNA Pharmaceuticals, Inc. 10801 Electron Drive, Suite 100 Louisville, KY 40299 www.magnaweb.com

References

Knollman, B., Chabner, B., & Brunton, L. (2011). Goodman & Gilman's *The Pharmacological Basis of Therapeutics*.

Rev. 3/17

Wallace, D. & Dykewicz, M. (2008). The diagnosis and management of rhinitis: an updated practice parameter. *Journal of Allergy and Clinical Immunology*, 122:S1-84